MDNA vs. AIM, FRX, ITH, CRDL, IPA, APM, GXE, GPH, WMD, and EQ
Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include Aimia (AIM), Fennec Pharmaceuticals (FRX), International Tower Hill Mines (ITH), Cardiol Therapeutics (CRDL), ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Graphite One (GPH), WeedMD (WMD), and EQ (EQ). These companies are all part of the "pharmaceutical products" industry.
Medicenna Therapeutics vs. Its Competitors
Aimia (TSE:AIM) and Medicenna Therapeutics (TSE:MDNA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.
In the previous week, Aimia had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 2 mentions for Aimia and 1 mentions for Medicenna Therapeutics. Aimia's average media sentiment score of 0.85 beat Medicenna Therapeutics' score of 0.55 indicating that Aimia is being referred to more favorably in the media.
Aimia has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.
Aimia currently has a consensus price target of C$4.00, suggesting a potential upside of 37.46%. Given Aimia's stronger consensus rating and higher probable upside, research analysts plainly believe Aimia is more favorable than Medicenna Therapeutics.
Medicenna Therapeutics has lower revenue, but higher earnings than Aimia. Aimia is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aimia has a net margin of -16.96% compared to Medicenna Therapeutics' net margin of -533,640.00%. Aimia's return on equity of -14.38% beat Medicenna Therapeutics' return on equity.
31.6% of Aimia shares are held by institutional investors. Comparatively, 13.0% of Medicenna Therapeutics shares are held by institutional investors. 3.3% of Aimia shares are held by insiders. Comparatively, 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Aimia beats Medicenna Therapeutics on 10 of the 16 factors compared between the two stocks.
Get Medicenna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicenna Therapeutics Competitors List
Related Companies and Tools
This page (TSE:MDNA) was last updated on 7/3/2025 by MarketBeat.com Staff
